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Background: The access to healthcare and treatment by rheumatoid arthritis (RA) patients, particularly to biologics,
differs significantly among European countries.
We aimed to explore the views and experiences of Portuguese healthcare stakeholders on key barriers which limit
the access to treatment, and ultimately to biologics, by RA patients and to find potential solutions (leverage points)
to overcome the identified barriers.
Methods: This was a qualitative research consisting of semi-structured face-to-face interviews with key stakeholders
in RA framework. Thirty four individuals from eight groups of stakeholders were interviewed: rural and urban general
practitioners (GPs), rheumatologists, hospital managers, hospital pharmacists, budget holders, representatives from the
Portuguese Rheumatology Society and the RA Patient Association. Interviews were conducted between May and June
2011. Conventional content analysis with research triangulation was used.
Results: The key barriers identified were related to the accessibility to primary healthcare services, difficulties in RA
diagnosis among GPs, inefficient referral to secondary healthcare and controlled process of biologics prescription in
public hospitals. The leverage points identified included the improvement of epidemiological and clinical knowledge
about RA in Portugal, a better understanding of the disease among patients and GPs, the clarification of biologics
benefits among budget holders and a raised awareness of the current treatment guidelines. In order to further address
the leverage points, the following key initiatives were proposed: optimization of RA national registry; dissemination of
information on rheumatic symptoms in primary care facilities and among the general public; increase interaction
between rheumatologists and GPs through clinical discussions of successfully treated patients or workshops; broader
utilization of disease diagnosis and monitoring tools, such as DAS28, and implementation of hospital–based research to
collect real-world data.
Conclusions: Most of the key barriers limiting the access to treatment, including biologics, in RA in Portugal are
upstream of rheumatology practice. Our findings suggest that future actions should be focused on the primary care
level to improve referral to rheumatologists. In addition, the collection of real-world data seems essential to characterise
the RA population, to improve disease management and to increase compliance with current treatment guidelines.
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Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease, which primarily causes a symmetric
polyarthritis, clinically manifested by joint pain, stiffness,
and swelling [1]. It is estimated to affect between 0.5 and
1.0% of the adult population in Western countries [2].
Untreated, most patients have a progressive course,
resulting in short- and long-term disability [3]. Evidence
shows that an early diagnosis and management of RA
can improve disease outcome [4-6]. The European League
Against Rheumatism (EULAR) recommends that patients
presenting with arthritis should be referred to and seen by
a rheumatologist, ideally within six weeks after the onset
of symptoms [7]. However, several studies have shown a
delayed access to the treatment by RA patients at different
settings [8-11].
The introduction of biologics in the late 1990s revolu-
tionized the management of RA. Despite its widespread
availability there are differences in the biologic drugs use
across Europe. Based on IMS sales data and adjusted es-
timates of RA prevalence in Europe Kobelt et al. esti-
mated a variation of biologics use ranging from 1% to
30% of the diagnosed adult patient population in 2008.
In Portugal, the observed proportion was 5.5%, the second
lowest among the smallest western markets in Europe.
Different factors can explain these variations. The two
most important are the macro-economic environment
and the treatment guidelines. The limited use of biologics
can be a consequence of low access to specialists and the
cost of biologics, the later contributing to restrictive treat-
ment guidelines and administrative constrains, most likely
related to GDP in each country [12]. These findings led
Laires et al. to conduct a desk-based research to compare
the proportion of RA patients treated with biologics across
Europe and to investigate the factors that most influence
its use, with focus on the Portuguese case. In 2010, less
than 7% of the estimated RA patient population was using
biologics in Portugal, which is noticeably lower than the
average rate of selected European countries (19%). This in-
vestigation also suggested that countries with the highest
levels of consumption of biologics showed superior
methotrexate consumption, higher GDP per capita and bi-
ologics retail distribution [13].
A desk research complemented by semi-structured in-
terviews to senior physicians and patient representatives
in France, Germany, Italy, Spain and UK, found that the
number of barriers conditioning the access to treatment
in RA varied considerably between those countries. The
main limiting factors included primarily delays in the
diagnosis of RA due to the lack of specialists available
and limited RA expertise among general practitioners
(GPs), resulting in slow referrals to the rheumatologists.
In addition, a low RA awareness in the population, con-
tributes to a late consultation with the GP, worseningthe global scenario. The access to biologics by patients
with a pre-existing RA diagnosis is limited by differences
in the reimbursement and prescription process and vari-
ations in the strictness of the treatment guidelines across
countries [14].
It is therefore pertinent to explore the views and expe-
riences of Portuguese stakeholders directly involved in
the RA therapeutic circuit and to identify the main bar-
riers to access treatment, and ultimately to biologics, in
order to improve this situation. To our knowledge, no
such research has been conducted in Portugal before.
This article, draws out the perspectives of its partici-
pants, presents qualitative findings regarding the key fac-
tors conditioning RA patient’s access to specialized
healthcare and appropriate treatment and identifies po-
tential solutions (leverage points).
Methods
In order to better understand the main barriers and pos-
sible leverage points a qualitative research was performed
using a semi-structured interview with key stakeholders in
Portugal. The interviews were conducted by researchers
qualified in qualitative research methods and independent
reviewers analysed the data.
Selection of stakeholders
The stakeholders were purposely selected based on their
involvement in the RA therapeutic circuit. Candidates
from eight groups of stakeholders were invited to take
part: GPs from urban and rural areas, rheumatologists,
hospital pharmacy managers and purchasers; hospital
managers; regional and national budget holders, repre-
sentatives from the Portuguese Society of Rheumatology
(SPR) and National RA Patient Association (ANDAR).
Physicians and hospitals from the most relevant geo-
graphical areas were selected. There was no predefined
number of interviews per stakeholder group. The inter-
views to each group of stakeholders continued until
overall data saturation was achieved, i.e. when no new
themes emerged and the same themes were reiterated.
Preliminary desk research
Preliminary desk research based on consultation of an
expert panel and relevant literature review [12] yielded
valuable information on the RA framework. From this
preliminary work an interview script was developed with
five pre-determined major research topics and related
questions: 1) Estimation of target RA patients; 2) Ac-
cess to healthcare services; 3) Access to RA treatment;
4) Treatment with biologics; 5) Hospital financing/man-
agement. These topics allow the characterisation of the
access to healthcare and treatment by RA patients. The
complete list of questions is displayed in Additional file 1.
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plore the views of stakeholders on potential barriers, le-
verage points and specific initiatives.
Interviews to the stakeholders
Face to face interviews were carried out between May
and June 2011. Upon the explanation of the research ob-
jectives by the interviewer a written informed consent
for data collection and publication of anonymous data
was obtained from all participants.
A trained and qualified interviewer followed a script
tailored to the background of the stakeholders with
questions covering the major research topics. Stake-
holders were encouraged to openly express their points
of view. Both the identified barriers, leverage points and
set of initiatives that could contribute to overcome the
barriers were debated between the interviewer and each
stakeholder. Each initiative was graded according to the
following criteria: attractiveness to stakeholders (not in-
teresting, likely interesting and clearly interesting) and
expected impact of the initiative in overcoming the iden-
tified barriers (low, medium and high).
Each interview lasted approximately 60 minutes and
was audio taped and later transcribed. In addition, inter-
viewer’s field notes documented the contextual details
and the non-verbal expressions of the interviewees,
which were useful in the data analysis and interpretation.
The interviewees were blinded about the funding of this
project.
Qualitative analysis
Conventional content analysis was used through immer-
sion/crystallization cycles as well as grounded theory ap-
proaches. The interviews were transcribed verbatim and
organised thematically by the interviewer. Two inde-
pendent researchers were involved in all the analysis
steps. First, the data was read to achieve a good know-
ledge of the content. Then, portions of data that wereTable 1 Major research topics addressed by each group of sta
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GPs: General practitioners, RA: Rheumatoid Arthritis, SPR: Portuguese Society of Rhesimilar in concept or idea were coded. For example, the
ideas related to the inefficient referral from primary
healthcare services or the waiting times at the hospital
were coded as “difficulties in accessing secondary health-
care services”. The concepts were compared between
transcripts and documents and in case of inconsistencies
data portions were re-coded. The codification and con-
cepts were also discussed between the researchers in
order to achieve consensus. Afterwards, the researchers
categorised each barrier identified under one of the five
major topics described (see Table 1). Each category was
associated with specific leverage points and initiatives.
Based on the content of the interviews the researchers
graded (as low, medium or high) each key initiative re-
garding the investment and effort required. No qualita-
tive analysis software was used to manage the data.
In order to confer more robustness, the main con-
clusions from the interviews, including the classifica-
tion attributed to each initiative, were consolidated in a
moderated group discussion involving one interviewee
from each group of stakeholders.
Qualitative research exploring the viewpoints and
opinions of healthcare professionals does not require
ethical approval in Portugal.
Results
There were thirty four participants in the project. Each
group of key stakeholders contributed with data from
one to nine individuals. All groups of stakeholders were
represented as planned (see Table 1).
Four key barriers limiting access to treatment, includ-
ing biologics, were identified as a result of the interviews
with stakeholders (see Table 2).
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Table 2 Key barriers identified by stakeholder group and level of agreement
Major research topic
based on RA circuit
Key barriers identified Level of agreement
U-GP R-GP REU PHA HMA SPR ANDAR
(n = 5) (n = 5) (n = 9) (n = 6) (n = 4) (n = 1) (n = 1)
Access to healthcare services a) Difficulties in accessing primary healthcare services 0/5 3/5 NA NA NA NA NA
b) Difficulties in RA diagnosis among GPs 0/5 1/5 9/9 NA NA 1/1 1/1
c) Difficulties in accessing secondary healthcare services 1/5 2/5 4/9 NA NA 1/1 1/1
Treatment with biologics d) Difficulties in accessing biologics NA NA 4/9 0/6 0/4 0/1 1/1
Level of agreement: number of stakeholders who recognised the issue as a key barrier in the RA circuit/ total sample interviewed among the group of
stakeholders, n: total sample interviewed among the group of stakeholders, NA: research topic not addressed by this group of stakeholders, RA: rheumatoid
arthritis, GPs: general practitioners, U-GP: urban general practitioner, R-GP: rural general practitioner, REU: rheumatologist, PHA: hospital pharmacy managers and
purchasers, HMA: hospital managers; SPR: Portuguese Society of Rheumatology, ANDAR: Rheumatoid Arthritis Patient Association.
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another relevant limitation in these regions.
However, these aspects were not valued by urban
GPs. Further, GPs believe there is a lack of
information regarding RA among the population,
which is often mistaken with other pathologies.
b) Difficulties in RA diagnosis among GPs
According to the rheumatologists, SPR and
ANDAR’s perspective, RA can be easily confused
with other rheumatic diseases and therefore difficult
to diagnose during the first appointments. In
addition, the time to perform complementary tests is
usually long, delaying the diagnosis. Due to
unawareness of its advantages or lack of funding for
it, the anti-cyclic citrullinated peptide (CCP) test is
not performed routinely in primary care. Anti-CCP
is a widely recognised tool for RA diagnosis and very
useful for non-rheumatologists who are not
experienced in joint examination [7]. GPs believe
that the availability of these tests would improve the
referral of RA patients to the specialist.
c) Difficulties in accessing secondary healthcare services
The group of professionals interviewed regarding
this topic, which included GPs, rheumatologists,
SPR, and ANDAR, referred that the waiting period
for a consultation with the specialist can vary
between regions. The access to a specialist is more
difficult in rural areas, as hospitals are distant, with a
deficient public transport network. From the
rheumatologists and SPR point of view, the waiting
time for a specialist consultation is usually decreased
if there is a strong suspicion of RA. On the other
hand, an imprecise or incorrect diagnosis in primary
care delays the first appointment with the specialist
consultant at the hospitals.
d) Difficulties in accessing biologics
The rheumatologists consider the approval of
biologics prescription by the hospital a bureaucratic
and controlled process. The patient medical history
has to be scrutinized and authorization has to beobtained from several parties, including the
department director, the prescribing specialist, the
hospital pharmacy, the therapeutic commission and
the Hospital Management Board, responsible for the
final decision. This process may take from two days
up to eight weeks. However, this complexity does
not impact on the rheumatologist decision to
prescribe biologics.
Moreover, rheumatologists noted that the criteria
used for biologics prescription differ between the
public and private setting, being more restrictive in
the former.
According to the representative of ANDAR, most
patients are unaware of the high added medical value
of biologics and consequently they do not bring this
subject into discussion during the consultation. This
situation is further aggravated by the fact that
patients, in general, have a passive relationship with
physician leading to unilateral treatment decisions.Identification of leverage points
The leverage points to overcome the identified barriers
to access treatment included the improvement of epi-
demiological and clinical knowledge about RA nationally,
a better understanding of the disease by the patients and
the GPs, the clarification of biologics benefits among
budget holders and a raised awareness of the current treat-
ment guidelines. Considering the identified leverage
points, eight key initiatives were proposed regarding its at-
tractiveness to stakeholders, its potential impact, the re-
quired investment and required effort (see Table 3).
Discussion
By exploring the views of individuals who in Portugal
represent the range of stakeholder groups involved in
the RA therapeutic circuit in Portugal, this study identi-
fied the main factors limiting access to healthcare and
treatment, and ultimately to biologics, and the key initia-
tives that may be undertaken to overcome these barriers.
Qualitative research methods were useful for this purpose
Table 3 Leverage points and key initiatives identified by stakeholders












clinical knowledge of RA
U-GP, R-GP,
REU, ANDAR





Dissemination of information on rheumatic
symptoms in primary care centres
Clearly interesting Medium Low Low
U-GP, R-GP,
REU, ANDAR





Regular visits of specialists to primary
healthcare centres
Clearly interesting Medium Low Medium
U-GP, R-GP,
REU, PHA
Regular training sessions about RA for GPs Clearly interesting Medium Low Low
Promote fulfilment of
biologics guidelines
REU, SPR Promote successful case reports about
biologic treatment
Likely interesting Medium Low Low
REU, SPR Promote broader utilization of diagnosis
and monitoring tools
Likely interesting Medium Low High
HMA, REU Implement hospital-based research to
collect real-world data
Clearly interesting Medium Medium Medium
Although barriers were identified, no leverage points resulted from the interviews with the budget holders.
*graded as: not interesting, likely interesting, clearly interesting. †graded as: low, medium, high.
U-GP: urban general practitioner, R-GP: rural general practitioner, REU: rheumatologist, ANDAR: Rheumatoid Arthritis Patient Association, PHA: pharmaceutical
managers and purchasers; SPR: Portuguese Society of Rheumatology, HMA: hospital managers.
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perience this research topic [15].
The most predominant view among stakeholders is
that relevant barriers in RA are upstream of the rheuma-
tology practice and consequently work needs to be done
at the primary care level.
The lower density of GPs in rural areas as well as the
unawareness of RA by the general population limits the
access to primary care services in this clinical context.
Access to rheumatologists is affected first by the geo-
graphical area of the patient, mainly in rural areas where
hospitals are located outside the residential areas; sec-
ond, by difficulties in diagnosing RA (which is often mis-
taken with other rheumatic diseases) at primary care
level. These factors result in a longer and ineffective re-
ferral process to the specialist, leading to the delay of
RA diagnosis and the postponement of the treatment
with disease-modifying antirheumatic drugs (DMARDs)
[11]. Many studies have shown that an early RA diagno-
sis and an aggressive management can limit the burden
of the disease [9-11]. Furthermore, there is evidence that
induction of remission early in the disease process can
impact on its progression [7,16,17]. In Europe, efforts
have been made to reduce time for RA diagnosis and
treatment, by promoting early diagnosis [14]. However,
because of different levels of disease awareness and di-
verse healthcare systems organisation, the success of
these initiatives differs between countries.
At the secondary care level the most relevant barrier
found was related to the difficulties in the approval ofbiologics prescription. These difficulties can be mainly
explained by the high cost of biologics and the hard
budget constraints observed in the Portuguese public
hospitals.
We cannot ignore the possible existence of other fac-
tors limiting access to biologics at the hospital level. For
example, although the lack of compliance to treatment
guidelines was proactively explored during the inter-
views none of the relevant stakeholders viewed this as a
key barrier to access to biologics.
Furthermore, none of the stakeholders believed there
was a barrier directly influencing first-line treatment with
non-biologic DMARDs (e.g. methotrexate) at the specialist
setting.
The leverage points most valued by the interviewees at
the primary care setting were focused on raising aware-
ness about the disease among patients and GPs. This
can be achieved by periodic and close interaction be-
tween rheumatologists and GPs, through regular visits
of these specialists to primary care centres, disease work-
shops, clinical discussions and e-training or other similar
activities. The analysis of successfully treated patients in
the context of the clinical discussion will motivate GPs to
diagnose and refer the patients to the specialist earlier.
Clear and lean referral recommendations could also help
GPs to identify cases requiring a specialist consultation.
Valorisation of RA among citizens must be enhanced
and patients should be more aware of the RA symptoms.
This could be achieved by awareness campaigns with the
involvement of the media and through dissemination of
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cilities. This sort of initiatives would have a considerable
impact on the promotion of the disease among the gen-
eral public.
The optimisation of the available registry of RA pa-
tients (Reuma.pt) [18] was a key initiative pointed out by
the RA Patient's Association, GPs and rheumatologists,
which aimed to improve knowledge about the disease
pattern in Portugal. This online register has a national
coverage, linking all public and private Rheumatology
Departments. Since June 2008, rheumatologists have
been collecting data on rheumatic patients receiving bio-
logic therapies or synthetic DMARDs. However, inter-
viewees noted that it is essential to professionalize this
registry process to ensure the data is reliable and updated.
This will certainly foster disease knowledge help monitor
patient’s conditions in the secondary care setting. Cur-
rently nationwide epidemiological programs, EpiReumaPt
[19] and CoReumaPt [20], are conducted to gather more
epidemiologic data and to evaluate the burden of different
rheumatic diseases in Portugal, including RA. The results
of this program will increase the overall knowledge of RA
and raise public awareness of the relevance of this condi-
tion and its impact on the Portuguese population. Ultim-
ately, it is expected that all these activities increase
patient’s access to treatment, which will contribute to a
global improvement in RA healthcare.
At the specialist setting the leverage points most val-
ued by the interviewed rheumatologists and HMA were
focused on the promotion of the benefits of biologics
and the fulfilment of specialists with treatment guidelines.
The most attractive initiative for stakeholders relates with
the implementation of hospital-based research to collect
real-world data. It is widely accepted that well-designed
observational studies can identify clinically important dif-
ferences among therapeutic options and provide data on
the long-term drug effectiveness and safety. This type of
studies can complement findings from randomized con-
trolled trials and therefore increase the clinician’s know-
ledge on the available treatments [21]. The interviewees
believe that hospital-based studies comparing cohorts of
RA patients using biologics versus other treatments would
provide a clearer picture about the biologics effectiveness,
safety profile and would allow a broader characterisation
of the treatment patterns in the daily practice. A large
electronic database, such as Reuma.pt, can be an invalu-
able resource for this type of research. A preliminary re-
port from this registry was published in January 2011
characterizing a pool of 2,162 RA patients of which 700
were treated with biologics and 1,462 with synthetic
DMARDs. This report characterised the average values
of disease activity, the duration of treatment with bio-
logics and the reasons for its discontinuation [18]. More
recently, another study based on REUMA.pt made acomparative effectiveness analysis of predictors of re-
sponse to tumour necrosis factor inhibitor therapies in
RA [22]. This type of reports will help to clarify the ef-
fectiveness of biologics in the Portuguese clinical prac-
tice and will contribute to compliance with treatment
guidelines.
Interestingly, two rheumatologists were apprehensive
regarding the long term safety profile of biologics, par-
ticularly the potential increased risk of infection. This
could suggest that concerns about hypothetical long-
term safety issues rose in the initial phase of the use of
biologics in the late 90’s have not been completely over-
come by rheumatologists. However, this aspect was not
considered a main barrier since only a minority of the
interviewees saw it as a key factor within RA treatment.
As long-term safety data for biologics are becoming
available from large observational cohorts, such as those
from national registries or from open label long-term ex-
tension of trials, it is reassuring to note that adverse ef-
fects tend to be more frequent in the early phase of
treatment [23]. Infection risk remains the major con-
cern, but it clearly peaks during the first months of use
and decreases over time to relatively low levels. Malig-
nancy was an initial concern, particularly for long-term
therapy but in fact all available data is reassuring regard-
ing this hypothetical issue [24].
The presentation of successful clinical cases related
to the use of biologics was seen by specialists as a
key initiative to promote its benefits and to demystify
apprehensions about the safety of these agents. This
initiative would require low investment and effort, in-
volving the cooperation between healthcare centres and
rheumatologists.
Rheumatologists believe that the use of RA evaluation
tools such as 28-joint count Disease Activity Score
(DAS28) should be encouraged. However, they recognise
that this initiative can demand a high amount of effort,
as it involves changing the established routine practices
of some rheumatologists who may not follow this prac-
tice in patients who are treated with conventional
DMARDs. DAS28 is an instrument to measure RA activity
with a composite score of several variables including ten-
derness and swelling of 28-joint counts, erythrocyte sedi-
mentation rate (ESR) and patient’s global assessment
through a visual analogue scale [25]. DAS28 has been
widely accepted as a valuable tool for measuring disease
activity [26] and worldwide guidelines on RA management
consider this parameter primordial. As in other countries,
in Portugal the guidelines for the use of biologics in RA
define specific disease activity levels (measured by DAS28)
[27]. DAS28 would not only support rheumatologists in
therapeutic decisions, but would also improve the fulfil-
ment of specialists with the treatment guidelines. There-
fore, from the specialist´s point of view, a wider use of
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management of the disease.Methodology discussion
We believe that the range of stakeholders groups se-
lected in our study represents the most relevant and in-
fluential professional areas involved in the therapeutic
circuit of RA in Portugal. The number of interviews per
stakeholder group was adequate since data overall satur-
ation method was followed. In addition, our study was
conducted within the most representative geographical
areas. Still, the perspective of the patient was not ex-
plored in this research. Patients are important stake-
holders in a therapeutic circuit and their involvement
would certainly enlighten our findings [28]. Nonetheless,
the Portuguese RA patient’s association (ANDAR) has a
large number of associates and systematically collects
their views, attitudes towards different problems, includ-
ing those linked to treatment. We believe that by explor-
ing the views of a representative from this association
we obtained a reliable overview of RA patients’ experi-
ences under this framework.
Although qualified and trained researchers were in-
volved, we cannot ignore the increased risk of inter-
viewer bias inherent to semi-structured interviews (e.g.
prescriptive or leading questions).
The use of data-triangulation allowed the validation of
the findings presented and conclusions were consoli-
dated by a final meeting with one representative of each
stakeholder group.
None the stakeholders involved had any vested interest
in the project, thus biased views can be excluded.Conclusions
The most predominant view emerged from this qualita-
tive study is that the most important barriers condition-
ing access to treatment by RA Portuguese patients, and
in particular to biologics, are upstream of rheumatology
practice. Actions should be implemented at the primary
care level to improve referral to rheumatologists and,
consequently promote the access to an adequate treat-
ment. This can be achieved by disseminating knowledge
about the disease among GPs and patients, by providing
the former with periodic and close interaction with
rheumatologists and the later with more information on
RA symptoms and the advantages of adequate treat-
ment. Long-term observational studies collecting daily
clinical activity data are essential to characterize the
local RA population, to improve disease management
and to increase compliance with the current treatment
guidelines. Increased communication and interaction be-
tween stakeholders in the RA treatment framework is
crucial to overcome existing barriers.Additional file
Additional file 1: Complete set of questions addressed by the
stakeholders. List of questions of the semi-structured interviews, tailored
to the background of the stakeholders.
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